Therefore, we used an indirect way to validate the predictive power of the ACB set by asking whether the biomarker profile, which has been identified through the selective TXNRD1 inhibitor DKFZ-682, is able to identify ROS-inducing drugs in a large collection of tool compounds and clinical drugs tested in NSCLC adenocarcinoma cell lines. The gene discussed is TXNRD1; the disease is adenocarcinoma.